Depletion of BIS sensitizes A549 cells to treatment with cisplatin

Molecular and Cellular Toxicology

Volumn 12, Issue 1, 2016, Pages 63-71

  Cui, Mei Nu ^a   Yun, Hye Hyeon ^a   Lee, Nan Ee ^b   Kim, Hye Yun ^a   Im, Chang Nim ^a   Kim, Yong Sam ^b,c   Lee, Jeong Hwa ^a  

^a The Catholic University of Korea   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c University of Science and Technology (UST)   (South Korea)

Author keywords

BIS; Cisplatin; HSF1; KRIBB11; Mcl 1

Indexed keywords

BCL 2 INTERACTING CELL DEATH SUPPRESSOR PROTEIN; CISPLATIN; ETOPOSIDE; ISOSORBIDE; KRIBB 11; MESSENGER RNA; PROTEIN; PROTEIN INHIBITOR; PROTEIN MCL 1; UNCLASSIFIED DRUG;

A549 CELL LINE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CRISPR CAS SYSTEM; GENE INACTIVATION; HUMAN; HUMAN CELL; LUNG CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; SENSITIZATION; WESTERN BLOTTING;

EID: 84962110863     PISSN: 1738642X     EISSN: 20928467     Source Type: Journal    
DOI: 10.1007/s13273-016-0009-y     Document Type: Article

References (42)

1. Jemal, A. et al. Global cancer statistics. CA Cancer J Clin61:69–90 (2011).
2. Youlden, D. R., Cramb, S. M. & Baade, P. D. Th International Epidemiology of Lung Cancer: geographical distribution and secular trends. J Thorac Oncol3:819–831 (2008).
3. Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E. & Adjei, A. A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc83:584–594 (2008).
4. Sandler, A. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med355:2542–2550 (2006).
5. Scagliotti, G. V. et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol26:3543–3551 (2008).
6. Schiller, J. H. et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med346:92–98 (2002).
7. Seah, S. et al. Activation of surrogate death receptor signaling triggers peroxynitrite-dependent execution of cisplatin-resistant cancer cells. Cell Death Dis6:e1926 (2015).
8. Lee, J. H. et al. Bis, a Bcl-2-binding protein that synergizes with Bcl-2 in preventing cell death. Oncogene18:6183–6190 (1999).
9. Zhu, H., Liu, P. & Li, J. BAG3: a new therapeutic target of human cancers? Histol Histopathol27:257–261 (2012).
10. Rosati, A., Graziano, V. De Laurenzi, V., Pascale, M. & Turco, M. C. BAG 3: a multifaceted protein that regulates major cell pathways. Cell Death Dis2:e141 (2011).
11. Jung, S. E. et al. Down-modulation o Bis sensitizes cell death in C6 glioma cells induced by oxygen-glucose deprivation. Brain Res1349:1–10 (2010).
12. Romano, M. F. et al. BAG3 protein controls B-chronic lymphocytic leukaemia cell apoptosis. Cell Death Differ10:383–385 (2003).
13. Liu, P., Xu, B., Li, J. & Lu, H. BAG3 gene silencing sensitizes leukemic cells to Bortezomib-induced apoptosis. FEBS Lett583:401–406 (2009).
14. Jacobs, A. T. & Marnett, L. J. HSF1-mediated BAG3 expression attenuates apoptosis in 4-hydroxynonenal-treated colon cancer cells via stabilization of anti-apoptotic Bcl-2 proteins. J Biol Chem284:9176–9183 (2009).
15. Chiappetta, G. et al. The antiapoptotic protein BAG3 is expressed in thyroid carcinomas and modulates apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. J Clin Endocrinol Metab92:1159–1163 (2007).
16. Li, N. et al. PKCdelta-mediated phosphorylation of BAG3 at Ser187 site induces epithelial-mesenchymal transition and enhances invasiveness in thyroid cancer FRO cells. Oncogene32:4539–4548 (2013).
17. Festa, M. et al. BAG3 protein is overexpressed in human glioblastoma and is a potential target for therapy. Am J Pathol178:2504–2512 (2011).
18. Rosati, A. et al. Expression of the antiapoptotic protein BAG 3 is a feature of pancreatic adenocarcinoma and its overexpression is associated with poorer survival. Am J Pathol181:1524–1529 (2012).
19. Falco, A. et al. BAG3 is a novel serum biomarker for pancreatic adenocarcinomas. Am J Gastroenterol108:1178–1180 (2013).
20. Rosati, A. et al. BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages. Nat Commun6:8695 (2015).
21. Zhang, Y., Wang, J. H., Lu, Q. & Wang, Y. J. Bag3 promotes resistance to apoptosis through Bcl-2 family members in non-small cell lung cancer. Oncol Rep27:109–113 (2012).
22. Chiappetta, G. et al. The anti-apoptotic BAG3 protein is expressed in lung carcinomas and regulates small cell lung carcinoma (SCLC) tumor growth. Oncotarget5:6846–6853 (2014).
23. Yeo, C. D. et al. Bis Expression in Patients with Surgically Resected Lung Cancer and its Clinical Significance. Ann Surg Oncol22(suppl 3):1365–1370 (2015).
24. Isaka, T., Nestor, A. L., Takada, T. & Allison, D. C. Chromosomal variations within aneuploid cancer lines. J Histochem Cytochem51:1343–1353 (2003).
25. Yoon, Y. J. et al. KRIBB11 inhibits HSP70 synthesis through inhibition of heat shock factor 1 function by impairing the recruitment of positive transcription elongation factor b to the hsp70 promoter. J Biol Chem286: 1737–1747 (2011).
26. Mani, J. et al. Knockdown of BAG3 sensitizes bladder cancer cells to treatment with the BH3 mimetic ABT-737. World J Urol (2015).
27. Li, S. et al. BAG3 promoted starvation-induced apoptosis of thyroid cancer cells via attenuation of autophagy. J Clin Endocrinol Metab99:E2298–2307 (2014).
28. Kong, D. H. et al. BAG3 sensitizes cancer cells exposed to DNA damaging agents via direct interaction with GRP78. Biochim Biophys Acta1833: 3245–3253 (2013).
29. Boiani, M., Daniel, C., Liu, X., Hogarty, M. D. & Marnett, L. J. The stress protein BAG3 stabilizes Mcl-1 protein and promotes survival of cancer cells and resistance to antagonist ABT-737. J Biol Chem288:6980–6990 (2013).
30. Moretti, L., Li, B., Kim, K. W., Chen, H. & Lu, B. AT-101, a pan-Bcl-2 inhibitor, leads to radiosensitization of non-small cell lung cancer. J Thorac Oncol5:680–687 (2010).
31. Mei, H., Lin, Z., Wang, Y., Wu, G. & Song, Y. Autophagy inhibition enhances pan-Bcl-2 inhibitor AT-101-induced apoptosis in non-small cell lung cancer. Neoplasma61:186–192 (2014).
32. Ren, T. et al. Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer. Drug Des Devel Ther9:2887–2910 (2015).
33. Akgul, C., Moulding, D. A., White, M. R. & Edwards, S. W. In vivo localisation and stability of human Mcl-1 using green fluorescent protein (GFP) fusion proteins. FEBS Lett478:72–76 (2000).
34. An, S., He, D., Wagner, E. & Jiang, C. Peptide-lik Polymers Exerting Effective Glioma-Targeted siRNA Delivery and Release for Therapeutic Application. Small11:5142–5150 (2015).
35. Wang, B. K. et al. Gold-nanorods-siRNA nanoplex for improved photothermal therapy by gene silencing. Biomaterials78:27–39 (2016).
36. Franceschelli, S. et al. Bag3 gene expression is regulated by heat shock factor 1. J Cell Physiol215:575–577 (2008).
37. Du, Z. X. et al. Proteasome inhibitor MG132 induces BAG3 expression through activation of heat shock factor 1. J Cell Physiol218:631–637 (2009).
38. Yoo, H. J., Im, C. N., Youn, D. Y., Yun, H. H. & Lee, J. H. Bis i Induced by Oxidative Stress via Activation of HSF1. Korean J Physiol Pharmacol18:403–409 (2014).
39. Zhang, X. & Qian, S. B. Chaperone-mediated hierarchical control in targeting misfolded proteins to aggresomes. Mol Biol Cell22:3277–3288 (2011).
40. Behl, C. BAG3 and friends: co-chaperones in selective autophagy during aging and disease. Autophagy7:795–798 (2011).
41. Yoon, T., Kang, G. Y., Han, A. R., Seo, E. K. & Lee, Y. S. 2,4-Bis(4-hydroxybenzyl)phenol inhibits heat shock transcription factor 1 and sensitizes lung cancer cells to conventional anticancer modalities. J Nat Prod77:1123–1129 (2014).
42. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat Protoc8:2281–2308 (2013).